Gri Bio Inc (GRI)

$2.28 +0.02 (0.88%)
Market Cap 3.27M
Revenue (ttm) 0.00
Net Income (ttm) -11.96M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 52,500
Avg Vol 92,102
Day's Range N/A - N/A
Shares Out 1.45M
Stochastic %K 50%
Beta -1.22
Analysts Sell
Price Target $25.00

Company Profile

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a no...

Industry: Biotechnology
Sector: Healthcare
Phone: 619 400 1170
Address:
2223 Avenida de la Playa, Suite 208, La Jolla, United States
BULLISH1975
BULLISH1975 May. 12 at 6:14 PM
$ICU the more research I fo anout iCU- The more bullish I get!!!!! so many medications fix one issue and cause more!!!! How often do we get a device which prevents organ damage- treats SEPSIS AnD prevents Dialysis????? 6 breakthrough device destinations Phase III trial the SCD already saving lives!!!! TAM billions float 4 million dyor $MTVA $GME $GRI $TLRY
0 · Reply
BULLISH1975
BULLISH1975 May. 12 at 3:23 PM
$ICU Q1 quarterly tomorrow- FDA SAVE news due AND ICU already showing as a BUY/STRONG BUY on several technical charts!!!!! Saving lives good momentum SCD becoming SOC TAM over 20 billion per chargpt 6 breakthrough device destinations one pediatric FDA HDE device and same device in adult phase III trial. $MTVA $ENSC $GME $GRI float is 4 million shares revenue growing- add to list
0 · Reply
BULLISH1975
BULLISH1975 May. 6 at 7:39 PM
$ICU up about 11% today! several catalysts due! TAM billions Device already pediatric FDA HDE approved- adult phase III readout in 12ish months- same device - market 50 times bigger! float 4 million 6 breakthrough device destinations $GME $ENSC $MTVA $GRI $GRIO dyor
0 · Reply
TruthTooPower
TruthTooPower May. 6 at 3:03 PM
$GRI!!! Don't be surprised when you wake up to Double Digits!!! Baby!!!
0 · Reply
BULLISH1975
BULLISH1975 May. 6 at 2:42 PM
$ICU last post for today!!!! This is a $30 stock sitting at $4.50. do your research people! lots of catalysts incoming, TAM billions- device saves lives!!! one fda HDE approved product one adult phase III no debt revenue growing $MTVA $ENSC $GRI $GME
0 · Reply
BillionerOfKing
BillionerOfKing May. 5 at 7:13 PM
$GRI Current Stock Price: $2.34
0 · Reply
TruthTooPower
TruthTooPower May. 5 at 4:20 PM
$GRI!!! This Is Riduculous $GRI Valuation Should Be In The Double Digits!!!
0 · Reply
BULLISH1975
BULLISH1975 May. 1 at 1:46 PM
$ICU **********If you new here! spend and hour researching and I am 99% certain you BUY!!!!!! Way under radar!!!! you will than me in a few weeks and months!!!!! lots if catalysts coming 4 million float approved device one phase III with TAM of 4 plus billion 6 breakthrough device destinations MC less than 18 million dyor $MTVA $GRI $CAR
1 · Reply
TruthTooPower
TruthTooPower Apr. 30 at 3:24 PM
$LASE!!! $IRD !!! $GRI !!! HELL YEAH!!! 🤓🤓🤓🙌🙌🙌🙌🤓🤓🤓
0 · Reply
nothximgood
nothximgood Apr. 30 at 1:33 PM
$GRI absolute trash stock
0 · Reply
Latest News on GRI
GRI Bio receives UAE patent allowance for inflammatory disease treatments

2026-04-08T13:21:10.000Z - 5 weeks ago

GRI Bio receives UAE patent allowance for inflammatory disease treatments

GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions

Apr 8, 2026, 8:30 AM EDT - 5 weeks ago

GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions

GRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” Segment

Feb 17, 2026, 9:15 AM EST - 3 months ago

GRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” Segment

GRI Bio Transcript: Corporate Connect Webinar Series

Feb 11, 2026, 1:00 PM EST - 3 months ago

GRI Bio Transcript: Corporate Connect Webinar Series

GRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

Feb 5, 2026, 9:15 AM EST - 3 months ago

GRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

GRI Bio sees cash runway into 1Q27

2026-02-04T13:50:33.000Z - 3 months ago

GRI Bio sees cash runway into 1Q27

GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights

Feb 4, 2026, 8:45 AM EST - 3 months ago

GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights

GRI Bio files $250M mixed securities shelf

2026-01-30T11:11:17.000Z - 3 months ago

GRI Bio files $250M mixed securities shelf

GRI Bio Inc trading resumes

2026-01-28T14:41:21.000Z - 3 months ago

GRI Bio Inc trading resumes

GRI Bio Inc trading halted, volatility trading pause

2026-01-28T14:35:28.000Z - 3 months ago

GRI Bio Inc trading halted, volatility trading pause

GRI Bio delivers additional data from Phase 2a study of GRI-0621

2026-01-28T13:56:26.000Z - 3 months ago

GRI Bio delivers additional data from Phase 2a study of GRI-0621

GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPF

Jan 28, 2026, 8:45 AM EST - 3 months ago

GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPF

GRI Bio secures U.S. composition of matter patent

2026-01-26T13:35:51.000Z - 3 months ago

GRI Bio secures U.S. composition of matter patent

GRI Bio Inc trading halted, news pending

2026-01-24T00:50:50.000Z - 3 months ago

GRI Bio Inc trading halted, news pending

GRI Bio announces 1-for-28 reverse stock split

2026-01-21T21:25:40.000Z - 3 months ago

GRI Bio announces 1-for-28 reverse stock split

GRI Bio Announces Reverse Stock Split

Jan 21, 2026, 4:01 PM EST - 3 months ago

GRI Bio Announces Reverse Stock Split

GRI Bio Transcript: EGM 2026

Jan 15, 2026, 9:00 AM EST - 4 months ago

GRI Bio Transcript: EGM 2026

GRI Bio announces data from Phase 2a study in Idiopathic Pulmonary Fibrosis

2026-01-08T13:39:21.000Z - 4 months ago

GRI Bio announces data from Phase 2a study in Idiopathic Pulmonary Fibrosis

GRI Bio Announces Closing of $8.0 Million Public Offering

Dec 12, 2025, 4:05 PM EST - 5 months ago

GRI Bio Announces Closing of $8.0 Million Public Offering

GRI Bio prices 10.67M shares at 75c in public offering

2025-12-11T14:20:13.000Z - 5 months ago

GRI Bio prices 10.67M shares at 75c in public offering

GRI Bio Announces Pricing of $8,000,000 Million Public Offering

Dec 11, 2025, 9:15 AM EST - 5 months ago

GRI Bio Announces Pricing of $8,000,000 Million Public Offering

GRI Bio announces GRI-0621-IPF-02 trial met primary, secondary endpoints

2025-12-10T21:41:18.000Z - 5 months ago

GRI Bio announces GRI-0621-IPF-02 trial met primary, secondary endpoints

GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

Dec 10, 2025, 4:05 PM EST - 5 months ago

GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

GRI Bio files to sell 5.13M shares of common stock, warrants

2025-12-08T13:25:31.000Z - 5 months ago

GRI Bio files to sell 5.13M shares of common stock, warrants

GRI Bio reports six-week lung function data in Phase 2a study of GRI-0621

2025-09-11T12:50:15.000Z - 8 months ago

GRI Bio reports six-week lung function data in Phase 2a study of GRI-0621

GRI Bio Reports 6-Week Interim Lung Function Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

Sep 11, 2025, 8:45 AM EDT - 8 months ago

GRI Bio Reports 6-Week Interim Lung Function Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

GRI Bio Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 9, 2025, 3:00 PM EDT - 8 months ago

GRI Bio Transcript: H.C. Wainwright 27th Annual Global Investment Conference

GRI Bio to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Aug 14, 2025, 9:15 AM EDT - 9 months ago

GRI Bio to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

GRI Bio CEO, Marc Hertz, Participates in Virtual Investor “What This Means” Segment

Jul 31, 2025, 1:50 PM EDT - 10 months ago

GRI Bio CEO, Marc Hertz, Participates in Virtual Investor “What This Means” Segment

GRI Bio reports 6-week interim biomarker results from Phase 2a study in IPF

2025-07-31T13:05:39.000Z - 10 months ago

GRI Bio reports 6-week interim biomarker results from Phase 2a study in IPF

GRI Bio Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Jul 22, 2025, 8:45 AM EDT - 10 months ago

GRI Bio Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

GRI Bio completes enrollment in Phase 2a study of GRI-0621

2025-07-01T12:50:17.000Z - 11 months ago

GRI Bio completes enrollment in Phase 2a study of GRI-0621

GRI Bio Completes Enrollment in Phase 2a Study of GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)

Jul 1, 2025, 8:45 AM EDT - 11 months ago

GRI Bio Completes Enrollment in Phase 2a Study of GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)

GRI Bio reports 6-week interim safety data from Phase 2a study of GRI-0621

2025-06-26T12:06:08.000Z - 11 months ago

GRI Bio reports 6-week interim safety data from Phase 2a study of GRI-0621

GRI Bio's GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

Jun 26, 2025, 8:00 AM EDT - 11 months ago

GRI Bio's GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

GRI Bio presents preclinical data on GRI-0621

2025-05-22T12:16:23.000Z - 1 year ago

GRI Bio presents preclinical data on GRI-0621

GRI Bio Transcript: Alliance Global Partners Healthcare Company Showcase

May 21, 2025, 2:40 PM EDT - 1 year ago

GRI Bio Transcript: Alliance Global Partners Healthcare Company Showcase

GRI Bio Transcript: A.G.P.'s Virtual Healthcare Company Showcase 2025

May 21, 2025, 2:40 PM EDT - 1 year ago

GRI Bio Transcript: A.G.P.'s Virtual Healthcare Company Showcase 2025

GRI Bio to Participate in the Virtual Investor Closing Bell Series

May 21, 2025, 9:15 AM EDT - 1 year ago

GRI Bio to Participate in the Virtual Investor Closing Bell Series

GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase

May 16, 2025, 9:15 AM EDT - 1 year ago

GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase

GRI Bio expects cash to fund operations through Q3 of 2025

2025-05-15T12:42:15.000Z - 1 year ago

GRI Bio expects cash to fund operations through Q3 of 2025

GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025

May 15, 2025, 8:35 AM EDT - 1 year ago

GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025

GRI Bio's Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

May 8, 2025, 8:45 AM EDT - 1 year ago

GRI Bio's Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)

May 7, 2025, 9:15 AM EDT - 1 year ago

GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)

GRI Bio Announces Abstract Selected for Poster Discussion Session at the 2025 American Thoracic Society (ATS) International Conference

Apr 16, 2025, 8:35 AM EDT - 1 year ago

GRI Bio Announces Abstract Selected for Poster Discussion Session at the 2025 American Thoracic Society (ATS) International Conference

GRI Bio Announces Closing of $5.0 Million Public Offering

Apr 2, 2025, 4:05 PM EDT - 1 year ago

GRI Bio Announces Closing of $5.0 Million Public Offering

GRI Bio Announces Pricing of $5.0 Million Public Offering

Apr 1, 2025, 11:15 AM EDT - 1 year ago

GRI Bio Announces Pricing of $5.0 Million Public Offering

GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan

Mar 31, 2025, 8:00 AM EDT - 1 year ago

GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan

GRI Bio Participates in a Virtual Investor CEO Connect Segment

Mar 18, 2025, 9:05 AM EDT - 1 year ago

GRI Bio Participates in a Virtual Investor CEO Connect Segment

GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)

Mar 17, 2025, 8:05 AM EDT - 1 year ago

GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)

GRI Bio Regains Compliance with Nasdaq's Minimum Bid Price Rule

Mar 11, 2025, 8:35 AM EDT - 1 year ago

GRI Bio Regains Compliance with Nasdaq's Minimum Bid Price Rule

GRI Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 19, 2025, 9:00 AM EST - 1 year ago

GRI Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds

Dec 23, 2024, 9:00 AM EST - 1 year ago

GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds

GRI Bio Showcases GRI-0621's Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF)

Nov 21, 2024, 8:45 AM EST - 1 year ago

GRI Bio Showcases GRI-0621's Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF)

GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis

Nov 14, 2024, 4:20 PM EST - 1 year ago

GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis

GRI Bio Raises a Total of $13.9 Million in Gross Proceeds Since the Beginning of 2024

Oct 24, 2024, 8:30 AM EDT - 1 year ago

GRI Bio Raises a Total of $13.9 Million in Gross Proceeds Since the Beginning of 2024

GRI Bio Announces Exercise of Warrants

Oct 21, 2024, 5:35 PM EDT - 1 year ago

GRI Bio Announces Exercise of Warrants

GRI Bio Presents Positive Preclinical Data Demonstrating GRI-0621's Ability to Inhibit Invariant Natural Killer T (iNKT) Cell Activity and Reduce Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)

Oct 16, 2024, 8:45 AM EDT - 1 year ago

GRI Bio Presents Positive Preclinical Data Demonstrating GRI-0621's Ability to Inhibit Invariant Natural Killer T (iNKT) Cell Activity and Reduce Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)

GRI Bio Granted Japan Patent for Proprietary Natural Killer T (NKT) Cell Modulators for Prevention and Treatment of Inflammatory Conditions

Sep 30, 2024, 8:30 AM EDT - 1 year ago

GRI Bio Granted Japan Patent for Proprietary Natural Killer T (NKT) Cell Modulators for Prevention and Treatment of Inflammatory Conditions

GRI Bio (NASDAQ: GRI) to Participate in a Virtual Investor CEO Connect Segment

Sep 25, 2024, 8:45 AM EDT - 1 year ago

GRI Bio (NASDAQ: GRI) to Participate in a Virtual Investor CEO Connect Segment

GRI Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 5, 2024, 8:45 AM EDT - 1 year ago

GRI Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

GRI Bio to Present at the 2024 European Respiratory Congress

Sep 4, 2024, 8:45 AM EDT - 1 year ago

GRI Bio to Present at the 2024 European Respiratory Congress

GRI Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 14, 2024, 8:05 AM EDT - 1 year ago

GRI Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update

GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Lunch Break Series

Jul 15, 2024, 9:05 AM EDT - 1 year ago

GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Lunch Break Series

GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment

Jul 11, 2024, 9:20 AM EDT - 1 year ago

GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment

GRI Bio Regains Compliance with Nasdaq

Jul 8, 2024, 9:05 AM EDT - 2 years ago

GRI Bio Regains Compliance with Nasdaq

GRI Bio Announces Publication of Positive Preclinical Data from Lead Program GRI-0621 in the American Journal of Respiratory and Critical Care Medicine

Jul 2, 2024, 9:05 AM EDT - 2 years ago

GRI Bio Announces Publication of Positive Preclinical Data from Lead Program GRI-0621 in the American Journal of Respiratory and Critical Care Medicine

GRI Bio to Present at the 8th Annual IPF Summit

Jul 1, 2024, 8:45 AM EDT - 2 years ago

GRI Bio to Present at the 8th Annual IPF Summit

GRI Bio Announces Closing of $4.0 Million Public Offering

Jun 28, 2024, 4:05 PM EDT - 2 years ago

GRI Bio Announces Closing of $4.0 Million Public Offering

GRI Bio Announces Korea Patent Granted for Proprietary Natural Killer T (NKT) Cell Modulators

Jun 27, 2024, 9:00 AM EDT - 2 years ago

GRI Bio Announces Korea Patent Granted for Proprietary Natural Killer T (NKT) Cell Modulators

GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment Highlighting Positive Preclinical Data from Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE) Programs

May 22, 2024, 9:15 AM EDT - 2 years ago

GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment Highlighting Positive Preclinical Data from Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE) Programs

GRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE)

May 21, 2024, 8:35 AM EDT - 2 years ago

GRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE)

GRI Bio Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)

May 20, 2024, 8:45 AM EDT - 2 years ago

GRI Bio Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)

GRI Bio to Present at Alliance Global Partner's 2024 Healthcare Company Showcase

May 14, 2024, 9:05 AM EDT - 2 years ago

GRI Bio to Present at Alliance Global Partner's 2024 Healthcare Company Showcase

BULLISH1975
BULLISH1975 May. 12 at 6:14 PM
$ICU the more research I fo anout iCU- The more bullish I get!!!!! so many medications fix one issue and cause more!!!! How often do we get a device which prevents organ damage- treats SEPSIS AnD prevents Dialysis????? 6 breakthrough device destinations Phase III trial the SCD already saving lives!!!! TAM billions float 4 million dyor $MTVA $GME $GRI $TLRY
0 · Reply
BULLISH1975
BULLISH1975 May. 12 at 3:23 PM
$ICU Q1 quarterly tomorrow- FDA SAVE news due AND ICU already showing as a BUY/STRONG BUY on several technical charts!!!!! Saving lives good momentum SCD becoming SOC TAM over 20 billion per chargpt 6 breakthrough device destinations one pediatric FDA HDE device and same device in adult phase III trial. $MTVA $ENSC $GME $GRI float is 4 million shares revenue growing- add to list
0 · Reply
BULLISH1975
BULLISH1975 May. 6 at 7:39 PM
$ICU up about 11% today! several catalysts due! TAM billions Device already pediatric FDA HDE approved- adult phase III readout in 12ish months- same device - market 50 times bigger! float 4 million 6 breakthrough device destinations $GME $ENSC $MTVA $GRI $GRIO dyor
0 · Reply
TruthTooPower
TruthTooPower May. 6 at 3:03 PM
$GRI!!! Don't be surprised when you wake up to Double Digits!!! Baby!!!
0 · Reply
BULLISH1975
BULLISH1975 May. 6 at 2:42 PM
$ICU last post for today!!!! This is a $30 stock sitting at $4.50. do your research people! lots of catalysts incoming, TAM billions- device saves lives!!! one fda HDE approved product one adult phase III no debt revenue growing $MTVA $ENSC $GRI $GME
0 · Reply
BillionerOfKing
BillionerOfKing May. 5 at 7:13 PM
$GRI Current Stock Price: $2.34
0 · Reply
TruthTooPower
TruthTooPower May. 5 at 4:20 PM
$GRI!!! This Is Riduculous $GRI Valuation Should Be In The Double Digits!!!
0 · Reply
BULLISH1975
BULLISH1975 May. 1 at 1:46 PM
$ICU **********If you new here! spend and hour researching and I am 99% certain you BUY!!!!!! Way under radar!!!! you will than me in a few weeks and months!!!!! lots if catalysts coming 4 million float approved device one phase III with TAM of 4 plus billion 6 breakthrough device destinations MC less than 18 million dyor $MTVA $GRI $CAR
1 · Reply
TruthTooPower
TruthTooPower Apr. 30 at 3:24 PM
$LASE!!! $IRD !!! $GRI !!! HELL YEAH!!! 🤓🤓🤓🙌🙌🙌🙌🤓🤓🤓
0 · Reply
nothximgood
nothximgood Apr. 30 at 1:33 PM
$GRI absolute trash stock
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 29 at 12:23 PM
$GRI
0 · Reply
TruthTooPower
TruthTooPower Apr. 29 at 12:19 PM
$GRI!!! GRI Bio Is Maintained at Buy by Ascendiant Capital
0 · Reply
TruthTooPower
TruthTooPower Apr. 29 at 12:19 PM
$GRI!!! GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions
0 · Reply
TruthTooPower
TruthTooPower Apr. 28 at 1:05 PM
$IRD!!! $LASE !!! $GRI !!! 🤓🤓🤓🤓🤓🤓🤓🤓🤓🤓😎
0 · Reply
BestNwest
BestNwest Apr. 26 at 8:22 PM
$GRI buy the dip,they said...price target 160$ and some analysts says 1008$,gonna see...
0 · Reply
ka1954
ka1954 Apr. 23 at 5:11 PM
$GRI this is the problem with this fucker. 32k shares only bring down 10%. this stock can't decide what to do
0 · Reply
SotirisGan
SotirisGan Apr. 22 at 12:40 PM
$GRI remember almost blowing my account on this shit
0 · Reply
SotirisGan
SotirisGan Apr. 22 at 11:29 AM
$GRI scam
0 · Reply
TruthTooPower
TruthTooPower Apr. 16 at 6:31 PM
$GRI!!! 🤓🤓🤓🤓🤓🙌🙌🙌🙌🙌 Ka1954 we got iit!!!
0 · Reply
LuckyRing
LuckyRing Apr. 13 at 3:09 PM
$GRI CEO has screwed the shareholders
0 · Reply
ka1954
ka1954 Apr. 13 at 3:06 PM
$GRI this stock is fucked up. went to 2.77 and now 2.20. what a joke
0 · Reply
LiveCommander
LiveCommander Apr. 10 at 6:27 PM
$GRI waking up 🤨 Recent 1-for-28 RS → float reset ~1.4M float 👉 still extremely thin No major catalyst → this is structure + momentum… Low float like this… volume hits → it moves fast! Watching closely 👀
0 · Reply